Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
The federal government just “liberated” health records. Here’s what that means.
Get advice from a Johns Hopkins physician on how to filter out the noise about COVID-19 and make smart, individualized decisi…
U.S. authorities say millions of Pine-Sol cleaning products could contain bacteria dangerous to those with weakened immune sy…
See a short video about a grassroots effort to make Halloween more fun for children who have food allergies and intolerances.
How can parents dealing with their own chronic pain teach children to manage pain in a healthy way? The authors of a just-pub…
CSL Behring sponsors an independent report that charts decades of progress in treating hemophilia and von Willebrand disease …
Get advice for declining invitations and claiming the time you need to refresh and recharge.
Back in-person, the annual conference left a lasting impact on the rare community.
Two accomplished scientists in Australia receive $1.25 million grants from CSL to continue their work studying malaria and bo…
Americas
Asia Pacific
Middle East
Europe
